Legend Biotech’s financial performance has been strong, with Carvykti sales showing significant growth. According to InvestingPro analysis, the company maintains a healthy financial position ...

The company’s flagship product, Carvykti, a CAR-T therapy for multiple myeloma, has demonstrated strong efficacy and is driving the company’s growth prospects. This comprehensive analysis examines ...

Morgan Stanley analyst Vikram Purohit lowered the firm’s price target on Legend Biotech (LEGN) to $80 from $82 and keeps an Overweight rating ...

Arcellx's innovative cell therapy platform shows promising potential in treating multiple myeloma, a significant unmet ...

Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how ...

Johnson & Johnson and Legend Biotech will arrive at next week's ASCO congress with a new EU approval for multiple myeloma CAR-T Carvykti. The European Commission has cleared Carvykti ...

Legend Biotech Corp (LEGN) reports a 110% increase in CARVYKTI sales, outlines expansion strategies, and anticipates profitability by 2026. Although the revenue and EPS for Legend Biotech (LEGN ...

Legend said last week that Carvykti made $55 million in the fourth quarter. Abecma, meanwhile, which came to market around a year before Carvykti, saw sales top the $100 million level in the third ...